Provider review
SnagRx Review: The 15% Is Right and the 1-2 lbs a Week Is Not
SnagRx makes two weight-loss claims in a single sentence, and only one of them survives its own evidence. "Lose up to 15% of your body weight" is close to what STEP-1 reported for semaglutide — the registry records −15.6% over 68 weeks. "(1-2lbs per week)" is not: 15.6% across 68 weeks averages about 0.23% of starting weight a week, and for one to two pounds a week to equal that, a patient would need to start at somewhere north of 400 lb. The magnitude is honest, the rate is two to four times what the trial produced, and the trial tested an approved drug rather than the compounded one SnagRx dispenses.
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens snagrx.com. A link is not a recommendation to take anything.
Provenance
What SnagRx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide Injections — Advertised at $69 against a struck-through $299. Its FAQ ties the discount to agreeing to a subscription length, so $299 is what a month costs without committing. ⚠ A footer promises you can "lock that pricing in for life" inches from a clock counting down to the price rising. Doseworth prices this company properly.
- Compounded Tirzepatide Injections — Advertised at $119 against a struck-through $399. ⚠ Its sibling brand Embody, the same operating company, strikes through $349 for the same compound — two undiscounted prices for one product under one owner.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 2 products reviewed here. The evidence belongs to the molecule, not to SnagRx.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from SnagRx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded Semaglutide InjectionsSemaglutide · Compounded (503A)Claim reaches past the trials
“Lose up to 15% of your body weight (1-2lbs per week) with medically supervised safe & effective treatment from the comfort of your home. […] It's not cheating, it's science! […] Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Registry-verified 2026-08-11: primary outcome "Change in Body Weight (%)", timeframe "Baseline (week 0) to week 68", reported as −15.6% on semaglutide 2.4 mg against −2.8% on placebo. The published paper reports −14.9% on a different estimand; both are real and the difference is the analysis, not the trial. It tested Novo Nordisk's approved injectable, not a compounded preparation.
The percentage is defensible and the weekly rate is not, and they are printed in the same sentence. STEP-1's −15.6% was measured over 68 weeks, which averages roughly 0.23% of starting body weight per week. For "1-2 lbs per week" to match that average a patient would have to start at about 435 to 870 lb; at any weight this drug is ordinarily prescribed at, the claim is two to four times the rate the trial produced. ⚠ In fairness: loss on these drugs is front-loaded, so the first weeks do run faster than the average — the objection is that a peak rate is being presented as the rate, with no period attached. ⚠ And the trial tested the approved product; what SnagRx dispenses is compounded and has never been through a registered trial. SnagRx does state that compounded medications are "not FDA-approved or evaluated for safety, efficacy, or quality" — but not next to the 15%.1
Compounded Tirzepatide InjectionsTirzepatide · Compounded (503A)Claim reaches past the trials
“Compounded Tirzepatide Injections — In Stock · $399 $119. […] Lose up to 15% of your body weight (1-2lbs per week) with medically supervised safe & effective treatment from the comfort of your home.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Registry-verified 2026-08-11: Completed, phase 3, 2,539 participants over 72 weeks, testing the approved injectable tirzepatide at a titrated therapeutic dose.
The same site-wide sentence covers this product, and the rate objection applies with equal force: SURMOUNT-1 ran 72 weeks, so even its larger reduction averages well under a pound a week for any ordinary starting weight. ⚠ There is a second problem specific to this row. The 15% figure comes from a SEMAGLUTIDE trial, and tirzepatide's own trial reported more than that — so a single blanket claim manages to overstate the rate for both products while understating the magnitude for one of them. A number applied to two different molecules is not a claim about either.2
Dispensing chain
Who actually fills your prescription
- Triad Rx — 26258 Pollard Road, Daphne, AL 36526, 251-380-7630, triadrx.us
Read the full account
SnagRx names its dispensing pharmacy in full, with a street address, a telephone number and a link to the pharmacy's own site — which most of this roster does not do at all. ⚠ What it does not state is the compounding category: neither 503A nor 503B appears anywhere, and the badge that stands in for one, "US-Certified Pharmacy", names no certifying body. ⚠ Its disclosure text says compounded GLP-1s are "produced in FDA-regulated facilities", which is loose in the usual direction — a 503A pharmacy is licensed and inspected by its state board, and a 503B outsourcing facility registers with FDA rather than being regulated by it in the sense the phrase implies.
Read on August 2026 from https://snagrx.com/
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result or testing laboratory is published. The nearest thing to a quality statement is the "US-Certified Pharmacy" badge, which names no certifying body, and the claim that the facilities are "highly regulated". ⚠ Naming the pharmacy does leave a reader somebody to ask, which is more than most of this roster offers.
Read on August 2026 from https://snagrx.com/
Licensing
Licensed to dispense, and where
Coverage
SnagRx's FAQ carries the question "What States/Jurisdictions are eligible?" and publishes no list, included set or excluded set on the page, so nothing here could be tested first-party and no coverage is claimed below.
Read the full licensing claim
"Doctor-prescribed GLP-1 treatment", with a provider writing the prescription after intake and "on-going care & support with SnagRx Nursing Staff". No clinician is named and no licensing detail is published.
Read on August 2026 from https://snagrx.com/
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its magnitude claim is close to the evidence: "up to 15%" sits between the −15.6% the registry records for STEP-1 and the −14.9% the published paper reports.
- It states plainly that compounded medications are "not FDA-approved or evaluated for safety, efficacy, or quality" — the exact disclosure two companies in this roster hold open FDA warning letters for omitting.
- It names its dispensing pharmacy with a street address, a phone number and a link to the pharmacy's own site.
Show 3 more
- Its testimonial copy carries an unusually complete disclaimer: patients "exercised daily and ate a reduced-calorie diet", and "their fat loss is not typical".
- It names the molecule on both products rather than selling "a GLP-1" of unstated composition.
- No FDA warning letter under the brand, the operating company or the named pharmacy — all three screened with a working positive control.
- "1-2lbs per week" is two to four times the average rate STEP-1 produced: 15.6% over 68 weeks is about 0.23% of starting weight a week, and no period is attached to the claim.
- One blanket figure — 15% — is applied to both semaglutide and tirzepatide, two molecules whose trials reported different results, so it cannot be an accurate claim about both.
- The 15% comes from a trial of the approved injectable, while SnagRx dispenses a compounded preparation that has never been through a registered trial. The disclosure exists, but not beside the number.
Show 4 more
- "Compounded GLP-1s are produced in FDA-regulated facilities" describes neither 503A pharmacies, which state boards license, nor 503B facilities, which register with FDA.
- No compounding category is stated anywhere, and "US-Certified Pharmacy" names no certifying body.
- SnagRx and Embody are the same operating company by both footers, and nothing on either site tells a reader comparing them so.
- No certificate of analysis, lot number or testing result is published for either product.
Verdict
The bottom line
SnagRx is worth reading carefully because it gets the hard part right and the easy part wrong. Its headline percentage is honest — "up to 15%" is what semaglutide's phase 3 trial actually produced, and plenty of companies reviewed here inflate that number freely. Then it puts "(1-2lbs per week)" in the same breath, and that is a different claim entirely: STEP-1's result averaged roughly a quarter of a percent of body weight per week, which for an ordinary starting weight is well under a pound. The rate is two to four times the evidence, the same 15% is applied to two molecules with different trial results, and both trials tested approved drugs rather than the compounded ones being sold. Against that, it names its pharmacy with an address and a phone number, and it prints the not-FDA-approved disclosure that two companies in this roster have open letters for omitting. It is also the same company as Embody, which nothing on either site mentions.
Opens snagrx.com. A link is not a recommendation to take anything.
Two claims in one sentence
SnagRx's footer promise:
"Lose up to 15% of your body weight (1-2lbs per week) with medically supervised safe & effective treatment from the comfort of your home."
Read as one claim it sounds coherent. Read as two, only one survives.
Full analysis — 5 more sectionsThe percentage is defensible · The weekly rate is not · One figure, two molecules · What it gets right · One company, two brands
The percentage is defensible
STEP-1 (NCT03548935) is the phase 3 trial of once-weekly semaglutide 2.4 mg in 1,961 adults. Registry-verified on 11 August 2026:
- Primary outcome — Change in Body Weight (%)
- Timeframe — Baseline (week 0) to week 68
- Result — −15.6% on semaglutide, −2.8% on placebo
The published paper reports −14.9% on a different estimand. Both are real; the difference is the analysis, not the trial. "Up to 15%" sits between them, which is more restraint than this category usually shows.
The weekly rate is not
15.6% spread across 68 weeks averages about 0.23% of starting body weight per week.
For "1-2 lbs per week" to equal 0.23% a week, a patient would have to start at roughly 435 to 870 lb. At any weight this drug is ordinarily prescribed at, one to two pounds a week is two to four times the average rate the trial produced.
Two things in fairness. Loss on these drugs is front-loaded, so the first weeks genuinely run faster than the 68-week average — the objection is that a peak rate is being presented as the rate, with no period attached. And this arithmetic deliberately avoids assuming a starting weight: the registry publishes the percentage and the timeframe, so the comparison is done proportionally rather than on a number nobody published.
One figure, two molecules
The same sentence sits above both products. But 15% comes from a semaglutide trial, and SnagRx also sells tirzepatide, whose own phase 3 program reported a larger reduction over 72 weeks. A single number applied to two different molecules overstates the rate for both and understates the magnitude for one. It is not a claim about either drug so much as a claim about the category.
What it gets right
"Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality."
That second sentence is the disclosure two companies in this review roster hold open FDA warning letters for leaving out. SnagRx prints it unprompted.
The first sentence is looser than it sounds. A 503A pharmacy is licensed and inspected by its state board; a 503B outsourcing facility registers with FDA. Neither is "FDA-regulated" in the way a reader will hear it.
It also names its pharmacy outright — Triad Rx, 26258 Pollard Road, Daphne, AL 36526, 251-380-7630 — which most of this roster never does.
One company, two brands
SnagRx's footer: "© 2026 SnagRx - Modern Metabolic Medicine, Inc."
Embody's footer: "Modern Metabolic Medicine, Inc. is the legal entity operating Embody (joinem.co)."
Same operator, same "$230 OFF every month" banner, same countdown clock, same $69 and $119 headline numbers. Nothing here claims the products are identical or the pharmacies shared — only that a reader treating these as two independent quotes is comparing one company with itself.
Questions
Frequently asked questions
Can you lose 1-2 lbs a week on compounded semaglutide?
Not as an average, on the evidence that exists. STEP-1 reported −15.6% of body weight over 68 weeks, which works out at roughly 0.23% of starting weight per week. For one to two pounds a week to match that, a patient would need to start at something north of 400 lb. Early weeks do run faster than the average because loss on these drugs is front-loaded, so a fast first month is not surprising — but presenting the peak rate as the rate, with no period attached, describes an outcome the trial did not produce.
Is "up to 15%" accurate?
Close, and unusually restrained for this category. The registry records STEP-1's primary outcome as −15.6% at week 68; the published paper reports −14.9% on a different estimand. "Up to 15%" sits between them. Two caveats: the trial tested Novo Nordisk's approved injectable rather than the compounded preparation SnagRx dispenses, and the same 15% is applied to its tirzepatide product, whose own trial reported a different result.
Is SnagRx the same company as Embody?
Yes, by both companies' own footers — SnagRx's names Modern Metabolic Medicine, Inc., and Embody's states that Modern Metabolic Medicine, Inc. is the legal entity operating Embody. They run the same promotional structure, the same discount banner and the same headline prices. That does not mean the products or pharmacies are the same, and nothing here claims they are; it means the two are not independent options.
Which pharmacy fills a SnagRx prescription?
Triad Rx, at 26258 Pollard Road, Daphne, AL 36526, 251-380-7630, published with a link to the pharmacy's own site. Naming it at all puts SnagRx ahead of most of this roster. What is missing is the compounding category — neither 503A nor 503B appears — and any certificate of analysis or testing result. Its "US-Certified Pharmacy" badge names no certifying body.
Glossary
Key terms
Show definitions
- Rate versus magnitude
- How fast weight comes off versus how much comes off in total. A trial reports magnitude over a stated period; dividing one by the other gives an average rate, which is lower than the early weeks and higher than the late ones. A weekly rate quoted without a period is the least checkable claim in this category.
- Estimand
- The precise question a trial's analysis answers — for instance, the effect of being assigned a treatment regardless of whether participants stayed on it, versus the effect of taking it as directed. STEP-1 reports −15.6% and −14.9% under two different estimands. Both are correct; they answer different questions.
- 503A pharmacy
- A compounding pharmacy licensed and inspected by its state board, preparing medicines for individual patients against a prescription. Its products are not FDA-approved and have not been evaluated by FDA for safety, effectiveness or quality.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off SnagRx's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.